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Summary
 
Insulin-dependent diabetes is heavily influenced by genes encoded within the major histocom-
patibility complex (MHC), positively by some class II alleles and negatively by others. We have
explored the mechanism of MHC class II–mediated protection from diabetes using a mouse
model carrying the rearranged T cell receptor (TCR) transgenes from a diabetogenic T cell
clone derived from a nonobese diabetic mouse. BDC2.5 TCR transgenics with C57Bl/6 back-
ground genes and two doses of the H-2
 
g7
 
 allele exhibited strong insulitis at 
 
z
 
3 wk of age and
most developed diabetes a few weeks later. When one of the H-2
 
g7
 
 alleles was replaced by H-2
 
b
 
,
insulitis was still severe and only slightly delayed, but diabetes was markedly inhibited in both
its penetrance and time of onset. The protective effect was mediated by the A
 
b
 
b
 
 gene, and did
not merely reflect haplozygosity of the A
 
b
 
g7
 
 gene. The only differences we observed in the T
cell compartments of g
 
7
 
/g
 
7
 
 and g
 
7
 
/b mice were a decrease in CD4
 
1
 
 cells displaying the trans-
gene-encoded TCR and an increase in cells expressing endogenously encoded TCR 
 
a
 
-chains.
When the synthesis of endogenously encoded 
 
a
 
-chains was prevented, the g
 
7
 
/b animals were
no longer protected from diabetes. g
 
7
 
/b mice did not have a general defect in the production of
A
 
g7
 
-restricted T cells, and antigen-presenting cells from g
 
7
 
/b animals were as effective as those
from g
 
7
 
/g
 
7
 
 mice in stimulating A
 
g7
 
-restricted T cell hybridomas. These results argue against
mechanisms of protection involving clonal deletion or anergization of diabetogenic T cells, or
one depending on capture of potentially pathogenic A
 
g7
 
-restricted epitopes by A
 
b
 
 molecules.
Rather, they support a mechanism based on MHC class II–mediated positive selection of T
cells expressing additional specificities.
 
T
 
he nonobese diabetic (NOD)
 
1
 
 mouse spontaneously
develops a disease with many of the characteristics of
insulin-dependent diabetes mellitus (IDDM) in humans
(for reviews see references 1 and 2). As such, it has become
the most frequently employed small animal model of
IDDM, and has permitted some important insights into the
complicated pathogenesis of this disorder.
One feature that NOD and human IDDM have in com-
mon is that genetic influences on the development and
progression of disease are very complex (for reviews see
references 3 and 4). Nonetheless, in both cases, the genetics
are dominated by one element, the MHC, which accounts
for 
 
.
 
30% of disease susceptibility (5–9).
The MHC of the NOD mouse is rather peculiar by sev-
eral criteria. H-2
 
g7
 
 is a naturally occurring recombinant lo-
cus, such that genes at the K end are of the d haplotype,
while at the D end they are of the b haplotype (5). The 
 
A
 
a
 
gene has the same coding sequence as 
 
A
 
a
 
d
 
, but the 
 
A
 
b
 
 gene
is a rare allele, otherwise found only in the Biozzi and a few
wild strains (10, 11); the resulting A
 
a
 
A
 
b
 
 heterodimer is ex-
pressed as usual at the cell surface, but appears to be of un-
usual conformation (12). The 
 
E
 
a
 
 gene has a promoter-region
mutation that precludes its transcription, and thereby ex-
pression of an E
 
a
 
E
 
b
 
 heterodimer at the cell surface (5).
Certainly, part of the MHC influence on the NOD disease
can be attributed to the presence of the A
 
g7
 
 complex. In-
deed, the A
 
b
 
g7
 
 chain carries His, Ser residues at positions
56, 57 rather than the Pro, Asp found in most other mouse
strains and thought to be diabetes-protective in humans
(10, 13). However, another part of the MHC could reflect
the absence of other A alleles or of the E complex.
Nishimoto and colleagues were the first to describe the
protective effect of introducing non-NOD MHC class II
genes onto the NOD genetic background (14–16). When
 
1
 
Abbreviations used in this paper:
 
 HEL, hen egg lysozyme; IDDM, insulin-
dependent diabetes mellitus; KLH, keyhole limpet hemacyanin; NOD,
nonobese diabetic; tg, transgenic.
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they introduced an 
 
E
 
a
 
 transgene, resulting in the surface
display of an E complex, they observed a striking protec-
tion from insulitis and diabetes. This result has since been
reproduced by several other groups using independent 
 
E
 
a
 
transgenes (17–19). In addition, there have been several re-
ports of similar findings after the introduction of various A
complex alleles or variants, although the extent of disease
inhibition was often less striking (8, 18, 20–23).
The mechanism by which non-NOD E and A genes
protect from disease in NOD mice remains a mystery. Sev-
eral possibilities have been raised, most with experimental
support both for and against. Possible mechanisms include
the following: (
 
a
 
) deletion of diabetogenic T cells or inhi-
bition of their selection (supported by references 24 and 25;
contested by references 17–19, 22, 26, 27); (
 
b
 
) anergization
of diabetogenic T cells (contested by references 22, 26, 27);
(
 
c
 
) diversion of the phenotype of diabetogenic T cells (sup-
ported by references 19, 22, 28); (
 
d
 
) “capture” of determi-
nants recognized by diabetogenic T cells (supported by ref-
erences 29, 30; contested by references 19, 26, 27, 31); (
 
e
 
)
positive selection of regulatory T cells (supported by refer-
ence 17; contested by references 26, 32); or (
 
f
 
) something
else.
Thus far, there is no general agreement on the mecha-
nism responsible for the protection from diabetes afforded
by MHC class II molecules. It is not even clear whether the
mode of inhibition by different class II molecules is the
same. The lack of consensus probably reflects certain prob-
lems inherent in the NOD system, i.e., the difficulty of
monitoring changes in the behavior of the very rare patho-
genic T cells, or the complexities resulting from genetic
manipulations.
Our strategy to begin dissecting the mechanism of MHC-
mediated protection has been to study the phenomenon in
the BDC2.5 TCR transgenic (tg) model of diabetes (27).
These mice carry the rearranged TCR genes from a CD4
 
1
 
T cell clone that is specific for a pancreatic islet 
 
b
 
-cell anti-
gen, is restricted by the A
 
g7
 
 molecule, and is diabetogenic (33).
Although self-reactive, the transgene-encoded specificity is
efficiently selected in animals expressing A
 
g7
 
 molecules and
makes an exaggerated contribution to the peripheral T cell
repertoire (27). On the NOD genetic background, there
are no signs of disease before 2 wk of age, with a rampant
insulitis beginning at three weeks, but no diabetes until
many months later (27). On the C57Bl/6 background, the
delay between the initiation of insulitis and onset of diabe-
tes is compressed to several weeks, at least in mice carrying
two doses of H-2
 
g7
 
 (33a).
We chose to examine MHC-mediated protective effects
in BDC2.5/C57 animals because of several advantages af-
forded by this system. First of all, diabetes occurs quite rap-
idly (before 8–10 wk of age) and with high incidence (usu-
ally 50–75%). In addition, the use of a TCR tg line, with
its high numbers of 
 
b
 
-cell–reactive T cells, should facilitate
elucidation of the mechanisms involved. Finally, using mice
with C57 background genes permits one to manipulate the
genome relatively easily, which makes use of available con-
genic and knockout lines without having to perform the
extensive serial backcrosses required with animals on the
NOD background. Introducing other MHC class II alleles
by breeding with MHC congenics rather than tgs has the
additional, very important, advantage of avoiding an aber-
rant phenotype that has been attributed to excess copies of
the 
 
A
 
b
 
 gene (34, 35)—a problem that has been highlighted
in one study (36) but completely ignored by most others.
Here, we describe our initial exploitation of this strategy,
the identification of an MHC class II molecule that protects
BDC2.5/C57 mice from diabetes, and elucidation of the
mechanism of protection at the cellular level.
 
Materials and Methods
 
Mice.
 
The generation of BDC2.5 TCR tg mice has been
previously described (27). The original founder was bred with a
C57Bl/6 mouse and successive offspring were backcrossed onto
the C57Bl/6 background for 11 generations. Backcrossed animals
were bred with B6.H-2
 
g7
 
 congenic mice (backcrossed 
 
.
 
26 gen-
erations onto the C57Bl/6 background; a gift from H. Kikutani,
Institute for Molecular and Cellular Biology, Osaka, Japan) and
the offspring intercrossed to generate B6.H-2
 
g7
 
 (referred to as g
 
7
 
/g
 
7
 
),
B6.H-2
 
g7/b
 
 (g
 
7
 
/b) and B6.H-2
 
b
 
 (b/b) littermates, all positive for
the BDC2.5 transgenes. All strains used in the other crosses to
generate experimental animals have been described before: 
 
E
 
a
 
16
 
tg mice, backcrossed to C57Bl/6 for 
 
.
 
30 generations (37); mice
lacking conventional MHC class II molecules (A
 
b8
 
) (38), back-
crossed to C57Bl/6 for 10 generations; and mice with a null mu-
tation in the TCR-
 
a
 
 locus (39), backcrossed 3 times to C57Bl/6.
Animals were typed for expression of the BDC2.5 transgenes
and for MHC status by FACS
 
Ò
 
 analysis of blood lymphocytes
(staining for V
 
b
 
4 and CD4 for BDC2.5, or with the mAbs Y3P,
specific for A
 
b
 
, and 10.2.16, reactive with A
 
g7
 
, reference 40). Ex-
pression of the E
 
a
 
16 transgene was checked using the mAb
14.4.4, specific for E molecules (41). Mice carrying mutations in
the A
 
b
 
 or TCR-
 
a
 
 locus were typed by Southern blot analysis of
tail DNA using probes specific for the A
 
b8
 
 and C
 
a8
 
 mutations,
respectively (38, 39).
All animals were maintained in our conventional facility, ac-
cording to European Economic Community guidelines.
 
Measurement of Diabetes and Insulitis.
 
Mice were followed for
diabetes weekly starting at 3 wk of age by testing urine glucose
levels (Uristix; Bayer Diagnostics, Puteaux, France); in addition,
during the interval between 3 and 11 wk of age, blood glucose
levels were measured every second week (Glucofilm strips read in
a Glucometer 3; Bayer Diagnostics). Animals were routinely fol-
lowed until they were 30 wk old. Mice were considered diabetic
if positive in two consecutive readings (urine glucose 
 
.
 
10 g/liter,
blood glucose 
 
.
 
300 mg/dl).
Hematoxylin and eosin staining of thin sections from Bouin’s
solution-fixed, paraffin-embedded pancreata was performed as pre-
viously described (17). For each animal, multiple sections of pan-
creas, with at least 40 islets, were scored for insulitis. Islets were
judged either free of insulitis, or suffering from periinsulitis (when
the infiltrate was limited to the surrounding ducts) or from true
insulitis (when there was entry of lymphocytes into the islets).
 
Antibodies and FACS
 
Ò
 
 Analysis.
 
The following mAbs were
used for T cell analysis, with immunostainings performed as pre-
viously described (38): PE-conjugated anti-CD4 (Caltag, South
San Francisco, CA); biotin-conjugated anti-CD8 (Caltag); FITC-
conjugated anti-CD69 (PharMingen, San Diego, CA); J11d, spe-
cific for heat-stable antigen; FITC-conjugated peanut agglutinin 
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(Sigma Chemical Co., St. Louis, MO); KT3, specific for CD3;
H57-597, specific for TCR-
 
a
 
/
 
b
 
; IM7, specific for CD44; Mel-14,
specific for CD62L; FITC-conjugated anti-CD31, clone MEC13.3
(PharMingen); FITC-conjugated anti-CD49d, clone R1-2 (Phar
Mingen); 16A, specific for CD45RB; PC61, specific for CD25;
PK136, anti-NK1.1 (PharMingen); and B20.1, RR 3-16, KT50,
and RR 8-1, specific for V
 
a
 
2, V
 
a
 
3.2, V
 
a
 
8, and V
 
a
 
11, respec-
tively (for references to mAbs see 27, 42, 43). Biotinylated anti-
body was revealed with Cy5-labeled streptavidin (Jackson Im-
munoResearch Labs., Inc., West Grove, PA), and the other
antibodies either with Texas red–labeled anti–rat IgG (Jackson
ImmunoResearch Labs., Inc.) or FITC-labeled anti–rat IgG (Caltag).
 
Production of T Cell Hybridomas and Assays of Reactivity.
 
6–10-
wk-old H-2
 
g7/b
 
 non-tg mice were immunized subcutaneously
with 50 
 
m
 
g of either hen egg lysozyme (HEL) or keyhole limpet
hemacyanin (KLH). 10 d later, the draining lymph nodes were
removed and, after in vitro restimulation with the appropriate an-
tigen, activated cells were fused with the myeloma cell line
BW5147 following a standard protocol (44). Growing hybrido-
mas were tested in a primary screen for antigen specificity using
splenocytes from g
 
7
 
/b mice as APCs. After 24 h, 50 
 
m
 
l of super-
natant was removed and the proliferation of the IL-2–dependent
CTLL cell line was used as a readout. Positive hybridomas were
subsequently checked for their MHC restriction using either sple-
nocytes from NOD (g
 
7
 
), B6.H-2
 
g7/b
 
 (g
 
7
 
/b) or B6 (b) mice as
APCs, including five serial dilutions of the appropriate antigen. In
the case of HEL, most of the hybridomas were restricted to either
g
 
7
 
 or b.
The BDC2.5 hybridoma was stimulated by freshly isolated islet
cells from DBA/2 mice (27), and IL-2 production was also mea-
sured using the CTLL assay.
 
Results
 
The H-2
 
b
 
 Complex, but not E Molecules, Can Protect
BDC2.5 TCR tg Mice from Diabetes.
 
To establish a system
for studying MHC-mediated protection from diabetes, we
evaluated the effect of non-NOD MHC genes on the de-
velopment of disease in BDC2.5 transgenics carried on the
C57 background.
First, we generated cohorts of littermates whose MHC
haplotype was either homozygous b/b, homozygous g
 
7
 
/g
 
7
 
,
or heterozygous g
 
7
 
/b. As expected from their inability to
positively select the BDC2.5 specificity (27), none of the
b/b mice showed signs of diabetes or insulitis (data not
shown). Both the g
 
7
 
/g
 
7
 
 and the g
 
7
 
/b animals developed di-
abetes, but there was a marked difference in both the pene-
trance and time of onset (Fig. 1 
 
A
 
). Although g
 
7
 
/g
 
7
 
 mice
had an average disease incidence of 57% at 12 wk of age,
only 21% of their g
 
7/b littermates were diabetic at this time
(P ,0.0001). A substantial proportion of g7/g7 animals was
already diabetic at 3 wk, whereas disease was rarely seen in
g7/b mice before 5 wk of age. In both cases, there were
very few additional diabetics after 10–12 wk of age.
To determine whether the significant decrease in diabe-
tes incidence seen for g7/b mice was accompanied by
changes in insulitis, we examined hematoxylin and eosin–
stained pancreas sections taken on different days, compar-
ing insulitis scores with reference data on a large number of
age-matched g7/g7 animals (Fig. 2). As has been reported
(33a), g7/g7 animals showed almost no infiltration at day
12, but showed an aggressive, overwhelming insulitis at day
18 in the vast majority of individuals. In contrast, in the g7/b
mice only a few islets were infiltrated at day 18, and even at
day 24 only a slight to moderate insulitis was observed. How-
ever, most of the islets were infiltrated at day 30, eventually
showing the same image of aggressiveness as seen for g7/g7
animals.
In a second set of experiments, we introduced an Ea
transgene into the BDC2.5/C57 line, thereby restoring
expression of E molecules. We had already shown that the
Ea transgene does not influence the slow-onset diabetes in
BDC2.5/NOD animals (27), but wondered whether it
would affect the more penetrant and more rapid disease in
BDC2.5/C57 animals; we also wanted to know whether it
would affect the protection seen with H-2b heterozygosity.
As shown in Fig. 1 B, we once again observed a marked
protection from diabetes in g7/b versus g7/g7 mice, but the
expression of E molecules had no detectable influence on
diabetes incidence in either g7/g7 or g7/b animals.
Thus, some element encoded in the H-2b complex af-
fords protection from diabetes in BDC2.5/C57 tg mice;
however, the E molecule is unable to do so. Comparing
g7/g7 and g7/b BDC2.5/C57 animals provides a system
where the only variable is a single dose of the H-2b com-
plex, offering the advantage that the introduced MHC
genes reside in their usual chromosomal context at the nor-
mal copy number.
Ab Molecules Are Responsible for the Protective Effect of the H-2b
Complex. Although it seemed likely that the protection
afforded by the H-2b complex was due to class II Ab mole-
cules (18, 20–22), it was possible that other elements might
Figure 1. The H-2b complex,
but not the E molecule, protects
BDC2.5/C57 tgs from diabetes.
(A) BDC2.5/C57 g7/g7 and g7/b
littermates were followed for di-
abetes; the percentage of diabetic
mice over time is indicated. The
data are pooled from several in-
dependent cohorts. (B) BDC2.5/
C57 g7/g7 and g7/b littermates,
carrying or not carrying the
Ea16 transgene, were monitored
for diabetes.382 MHC-mediated Protection from Diabetes Via Positive Selection
be responsible, in particular, class I molecules (45, 46) or
the TNFs (47). To test the role of Ab molecules, we took
advantage of the Ab8 line of mice, which carries essentially
only C57 background genes (after 10 backcrosses) and all of
the genes of the H-2b complex but has an engineered null
mutation at the Ab locus. By appropriate breedings, we
produced BDC2.5/C57 littermates that were either b/b8,
g7/g7, g7/b or g7/b8. As can be seen in Fig. 3, the b/b8,
g7/g7 and g7/b animals had the expected incidence rates of
zero, quite high and low, respectively. The g7/b8 mice, un-
able to express Ab molecules, showed the same incidence as
g7/g7 animals.
This result permits us to conclude that the protection
from diabetes afforded by the H-2b complex is due to the
presence of Ab molecules. It cannot be attributed to other
molecules encoded within H-2b, nor is it the trivial result
of having a single, rather than two, doses of the Ag7 allele.
g7/b BDC2.5/C57 tgs have Fewer Mature CD41 T Cells
and More Cells Expressing Endogenously Encoded TCR-a
Chains. One of the major advantages of the BDC2.5
TCR tg system is that the exaggerated frequency of T cells
displaying the transgene-encoded specificity permits one to
study just how MHC-mediated protection impinges on a di-
abetogenic T cell. Thus, we compared the T cell compart-
ments in the thymus and peripheral organs of 4–6-wk-old
nondiabetic g7/g7 and g7/b BDC2.5/C57 tgs, concentrat-
ing on cell numbers, expression of the transgene-encoded
clonotype versus endogenously encoded TCR chains, and
expression of activation markers.
The total number of thymocytes was comparable in g7/g7
and g7/b BDC2.5/C57 mice (Fig. 4 A), suggesting that
massive clonal deletion did not take place in the latter. The
CD4/8 staining profiles of thymocytes from both types of
animals revealed a strong bias for CD4182 versus CD4281
cells (Fig. 4 B), as was previously seen for BDC2.5 tgs on
the NOD background (27). However, the percentage of
mature CD41 T cells and their total numbers (Fig. 4 C)
were about twice as high in g7/g7 animals as in their g7/b
littermates. This difference was also reflected in the histo-
grams of TCR-a/b expression, where g7/g7 animals had
more mature cells expressing high receptor levels (Fig. 4 D).
No differences between the two types of mice were evi-
dent in the staining patterns for heat-stable antigen, peanut
agglutinin, and CD69, maturation markers correlated with
positive selection (data not shown).
The transgene-encoded BDC2.5 TCR carries the Vb4
and Va1 variable regions (48). Unfortunately, no anti-Va1
reagent is presently available, so we could not directly
quantitate the BDC2.5 clonotype, but we could estimate
the use of endogenously encoded TCR-a chains by stain-
ing for Va2. In both g7/g7 and g7/b mice, .95% of the
Figure 2. The onset of insuli-
tis is delayed in g7/b BDC2.5 tgs.
BDC2.5/C57 transgenic mice
(g7/g7 or g7/b haplotype at the
MHC) were killed on days 12,
18, 24, or 30, and the percentage
of pancreatic islets showing ei-
ther periinsulitis or insulitis was
quantitated. Each bar represents an
individual mouse. The white por-
tion of the bars indicates periin-
sulitis, the black portion insulitis.
Figure 3. The protective effect of the H-2b complex can be attributed
to Ab molecules. BDC2.5/C57 transgenic mice were bred with g7, b, or
b8 haplotypes at the MHC. The latter is a mutant H-2b complex carrying
a null mutation at the Ab locus (38). Littermates from these crosses were
followed for diabetes.383 Lühder et al.
CD4182 thymocytes were positive for Vb4, demonstrating
the almost complete allelic exclusion of the TCR-b gene
in both cases (data not shown). In contrast, exclusion at the
TCR-a locus differed in the two types of mice: there was
repeatably twice the percentage of CD4182 cells express-
ing Va2 in g7/b than in g7/g7 animals, signifying a greater
usage of endogenously encoded Va chains in the former
(data not shown). Parallel results were obtained using anti-
Va3.2, -Va8, and -Va11 reagents, ruling out the possibil-
ity that the Vb4 chain preferentially paired with particular
endogenously encoded Vas (data not shown).
These results were mirrored in the periphery, and some-
times even exaggerated. Total numbers of T cells in the
spleen and lymph nodes were comparable in g7/g7 and g7/b
littermates (data not shown). The same skewing in favor of
CD41 T lymphocytes was observed (Fig. 4 E) and, again,
there were more mature CD41 T cells in g7/g7 than g7/b
mice (Fig. 4 F). Because there were more CD81 T cells in
the periphery of g7/b mice, the difference in the CD4/8
ratios was even more striking than in the thymus, averaging
about 50 in homozygotes in contrast to only 15 in het-
erozygotes.
The difference in expression of endogenously encoded
TCR-a chains was also more pronounced in the periphery
(Fig. 4, G and H). In the g7/g7 BDC2.5/C57 tgs, Va2 was
displayed on only 20% as many T cells as in non-tg C57Bl/6
controls; in g7/b BDC2.5/C57 mice, 80% as many did.
Many more of the T cells in the g7/b transgenics had inter-
mediate levels of Va2 expression than is normally found in
nontransgenic C57Bl/6 controls. Assuming (a) that such cells
express two TCRs, the transgene-encoded Vb4Va1 recep-
tor and another consisting of Vb4 paired with an endoge-
nously encoded Va chain, and (b) that there is no preferen-
tial pairing, it can be calculated that 80% of the peripheral
T cells in g7/g7 mice displayed only the BDC2.5 TCR,
12% expressed it together with another receptor, and 8%
displayed only another receptor; the contrasting corre-
sponding values for g7/b mice are 20, 40, and 40%. Thus, a
far greater proportion of cells expressing endogenously en-
coded Va chains was present in g7/b animals.
No difference was observed between the two kinds of
mice regarding expression of early (CD69, CD25) or late
(CD44, CD62L, CD45RB, CD45RC) activation markers,
nor regarding the display of adhesion molecules (CD31,
CD49d). Both g7/g7 and g7/b transgenics showed a re-
markable reduction in NK T cells (NK1.11, CD31), prob-
ably a reflection of the TCR transgenes, but there was no
significant difference between the two (data not shown).
In summary, the only differences we observed in the T
cell compartments of g7/g7 and g7/b BDC2.5/C57 litter-
mates were a twofold drop in the number of mature CD41
cells and a marked rise in the number of cells expressing
endogenously encoded TCR-a chains, alterations first ob-
served in the thymus and exaggerated in the periphery.
High Diabetes Incidence Is Restored in g7/b BDC2.5/C57
tgs Incapable of Expressing Endogenously Encoded TCR-a
Chains. The previously described Ca8 mutation (39),
which eliminates the expression of endogenously encoded
TCR-a chains, permitted us to directly test whether there is
a causal relationship between the increased expression of
additional receptors in g7/b BDC2.5 transgenics and their
reduced incidence of diabetes. The appropriate crosses
yielded a panel of littermates that were g7/g7 or g7/b and
carried or did not carry the homozygous Ca8 mutation. g7/g7
Figure 4. In g7/b BDC2.5 TCR tg mice, there are fewer CD41 T cells and more cells that express endogenously encoded TCR-a chains. (A) Total
numbers of thymocytes in g7/g7 and g7/b littermates from 10 different experiments; each dot represents an individual mouse; the average values are
shown (g7/g7: 159.5 6 78.3 millions, g7/b: 160.4 6 75.4 millions). (B) Representative CD4/CD8 cytofluorimetric profiles; the percentage of CD4182
cells is indicated. (C) Numbers of CD4182 cells; the average values are shown (g7/g7: 24.8 6 11.7 millions, g7/b: 10.3 6 6.2 millions, P ,0.003). (D)
Representative histogram of CD3 expression on total thymocytes. (E) Representative CD4/CD8 profiles of mesenteric lymph node lymphocytes, gated
on CD3-positive cells. The percentages of CD41 and CD81 cells are indicated. (F) Percentage of CD41 cells for g7/g7 and g7/b littermates; each dot rep-
resents an individual mouse; the average values are shown (g7/g7: 20 6 8.9 millions, g7/b: 11.6 6 4.1 millions, P ,0.005). The total number of lymph
node cells did not differ significantly in the different mice. (G) TCR-ab/Va2 profiles of CD41 T cells; the two gates delineate the Va2hi and Va2int
populations; in normal C57Bl/6 mice taken as a reference, the vast majority (80–90%) of Va2-positive CD41 cells fell within this Va2hi gate. (H) Black
bars represent proportion of cells expressing an endogeneous Va chain (relative to C57Bl/6); white bars represent proportion of cells expressing low lev-
els of an endogeneous Va chain (most likely in conjunction with the tg Va), also relative to C57Bl/6. Each bar represents an individual mouse.384 MHC-mediated Protection from Diabetes Via Positive Selection
animals developed diabetes similarly in the presence or ab-
sence of the mutation (Fig. 5 and data not shown). Strik-
ingly, the low incidence of disease characteristic of g7/b
mice was reverted in the presence of the Ca8 mutation in
homozygous form, the time of onset and the penetrance
both being equivalent to that of g7/g7 animals.
We also assessed the efficiency of selecting CD41 T cells
in the same panel of littermates. g7/b animals carrying the
homozygous Ca8 mutation showed the same deficiency in
numbers of CD4182 cells in the thymus and CD41 cells in
the peripheral lymphoid organs as did their g7/b littermates
with a wild-type Ca locus (data not shown).
These observations argue that the increase in T cells with
additional TCR specificities is responsible for the protec-
tion from diabetes in g7/b BDC2.5/C57 tgs. Were these
additional specificities to be causally related to MHC-
mediated protection from diabetes, one would expect that
g7/g7 BDC2.5/C57 tgs carrying an Ea transgene or g7/b8
BDC2.5/C57 animals, neither of which are protected from
diabetes, should express low levels of endogenously en-
coded TCR-a chains, as straight g7/g7 TCR tgs do. This
expectation proved correct (data not shown).
The Ag7 Molecules on g7/b APCs Can Function Effectively in
T Cell Selection and Activation. As a first step in defining
what underlies the changes in T cell repertoire observed in
g7/b BDC2.5 tgs, we compared the ability of the Ag7 mol-
ecules expressed on g7/g7 and g7/b cells to function in dif-
ferent contexts. It was possible that coexpression of Ab
molecules could compromise the ability of Ag7 molecules
to present peptides effectively. Such an effect has been ob-
served with other pairs of class II molecules, concerning
both thymic selection of T cells (49) and their peripheral
activation (50, 51), and might be expected with Ag7 mole-
cules, given their unusual conformation at the cell surface
probably reflecting poor peptide binding (12).
To test this, we first injected non-tg g7/b mice with
HEL, re-stimulated draining lymph node cells in the pres-
ence of HEL, and generated a panel of HEL-specific T cell
hybridomas. From 4 experiments, we obtained a total of 31
g7-restricted and 48 b-restricted hybridomas. This experi-
ment, capable of assessing both thymic selection and pe-
ripheral stimulation, but incapable of discriminating be-
tween them, ruled out a gross defect in the function of Ag7
in the presence of Ab molecules.
Secondly, we compared the ability of APCs from non-tg
g7/g7 and g7/b animals to present antigen in vitro to differ-
ent g7-restricted T cell hybridomas (Fig. 6). APCs from the
two types of animals were equally efficient at presenting to
HEL- and KLH-specific T cell hybridomas and, most im-
portantly, to the hybridoma expressing the same receptor as
the BDC2.5 TCR tg line. This experiment confirmed that
Ab molecules do not prevent Ag7 molecules from effectively
presenting antigens to T cells.
Discussion
Exploiting the advantages of the BDC2.5 TCR tg
model, we have probed the mechanism of MHC-mediated
protection from IDDM. We found that BDC2.5/C57 tgs
that carried one H-2b allele, more specifically, an Abb al-
lele, had a lower penetrance and slower onset of diabetes
than littermates homozygous for H-2g7. That this protec-
tion was not due to massive Ab-mediated clonal deletion of
cells expressing the BDC2.5 specificity is argued by several
observations: thymocyte numbers were normal (Fig. 4, A
and B); there seemed to be plenty of clonotype-positive T
cells in the peripheral lymphoid organs (Fig. 4, G and H),
and T cells invaded the islets en masse (Fig. 2). T cell hom-
ing to and maintenance in the islets of g7/b mice also sug-
gests that disease inhibition was not a reflection of clonal
anergy, at least as conventionally considered. That protection
was not due to capture by Ab molecules of the Ag7-restricted
epitope recognized by BDC2.5 T cells is indicated by their
invasion of the islets in g7/b mice in vivo and the ability of
the corresponding hybridoma to be stimulated by hybrid
APCs in vitro (Fig. 6).
Rather, our data highlight an effect on positive selection.
Figure 5. Introduction of the TCR-a8 mutation restores high diabetes
incidence in g7/b mice. BDC2.5/C57 mice (g7/g7 or g7/b haplotypes at
the MHC) were bred with the TCR-a–null mutation. Ca8 homozygotes
or Ca1 littermates were followed for diabetes (since there was no differ-
ence between homozygous and heterozygous wild-type animals, the data
were pooled, indicated as Ca1). The diabetes incidence for Ca8 g 7/g7
mice did not differ from that of Ca1 littermates and is therefore not
shown here for clarity.
Figure 6. APCs from both g7/g7 and g7/b mice present antigen effi-
ciently to Ag7-restricted T cell hybridomas. The BDC2.5 hybridoma or
g7-restricted hybridomas specific for HEL or KLH epitopes [HEL(g7) 4B12
and KLH(g7)5D2, respectively] were challenged with APCs from non-tg
g7/g7 or g7/b animals. The antigen titration curves were made with islet
cells or with HEL or KLH protein, and IL-2 production was read-out as
[3H]thymidine incorporation by the IL-2–dependent CTLL cell line.385 Lühder et al.
Ab-mediated protection from diabetes was accompanied by
both a decrease in CD41 T cells displaying the transgene-
encoded clonotype and an increase in cells expressing other
clonotypes, specified by endogenously encoded TCR-a–
chains. Low diabetes incidence was not always correlated
with the former, but always depended on the latter. Thus,
in this system, MHC-mediated protection from IDDM re-
flects the ability of an additional class II molecule to posi-
tively select T cells expressing additional TCR specificities.
How might these T cells influence the progression of di-
abetes? Possible mechanisms depend on whether the dis-
ease-modulating cells are those which express only recep-
tors carrying an endogenously encoded TCR-a chain or are
those expressing the BDC2.5 clonotype plus such recep-
tors, the distinction being additional cells versus just addi-
tional receptors. Additional cells could exert their influence
by creating a cytokine/chemokine milieu that alters the
phenotype or behavior of the diabetogenic cells, e.g., by
skewing their T helper phenotype or influencing their dis-
position, or that of accessory cells within the islets. They
might also act as clonotype-specific suppressor cells, like
those described in other systems (52–55). In our system,
such suppression could not involve massive deletion of the
clonotype-positive targets since they were always present in
abundance (Fig. 4 B). Additional receptors on cells express-
ing BDC2.5 TCRs could alter the quality of the response
to the b cell antigen. It is now clear that the “strength”
with which a T cell is stimulated dictates the subsequent
response mode (i.e., how much it proliferates, what cyto-
kines it produces, what other effector functions are mobi-
lized, whether it is activated or anergized [56–58]). As
mentioned, anergy induction would seem unlikely in this
case, given that the BDC2.5 T cells did invade the islets,
but this possibility can be directly tested in ex vivo activa-
tion or transfer experiments.
Interestingly, although Ab molecules had a protective ef-
fect on diabetes in BDC2.5/C57 tgs, E molecules did not.
Two explanations for the difference seem possible. It could
be that the mechanism of protection is different with dif-
ferent class II molecules. In fact, this notion has been sug-
gested before to account for the observation that some class
II molecules almost completely protect NOD mice from
diabetes and insulitis (14–21), whereas others only partially
inhibit diabetes and hardly influence insulitis (22, 23). Al-
ternatively, it could be that all of the class II molecules op-
erate by the same mechanism, but that they have different
efficiencies, which may be amplified by threshold effects.
Specifically in regard to the BDC2.5 TCR tg model, it re-
mains possible that E molecules would exert a negative in-
fluence if confronted with less overwhelming numbers of
diabetogenic T cells.
Our data contrast with a recent report on similar experi-
ments on MHC-mediated protection using a TCR tg line
derived from a different b cell–specific T cell clone (25). In
that system, several MHC class II molecules inhibited the
development of diabetes, all purportedly because they pro-
voked massive clonal deletion of the diabetogenic T cells
expressing the transgene-encoded receptor. As discussed
above, substantial clonal deletion did not occur in the
BDC2.5 system. The differences between these two sets of
results could be an illustration of the notion that different
MHC molecules might use different means to protect from
disease. However, it seems that clonal deletion is not the
major mode of A-mediated protection in the NOD system:
Abb (8), Abk (26), Abd (22), and a mutant of Abg7 (23) in-
hibit diabetes development, but islet-reactive, potentially
diabetogenic T cells remain detectable, as indicated by their
ability to infiltrate the pancreatic islets, provoke diabetes
upon cyclophosphamide treatment, and/or transfer diabetes
to lymphocyte-deficient NOD recipients.
Two features of MHC-mediated protection from diabe-
tes have always been perplexing. First, how can so many
different alleles have an inhibitory influence? Second, how
can certain molecules inhibit diabetes but exacerbate other
autoimmune diseases (for example, see reference 28)? The
mechanism we suggest to explain Ab-mediated protection
in the BDC2.5/C57 model would provide answers to these
questions: the different MHC alleles can all promote the
positive selection of T cells with additional specificities; a
given MHC molecule could select a repertoire which in-
cludes some T cells that are able to downmodulate diabe-
tes, and others that can amplify autoimmune attack on an-
other tissue.
Detailing the mechanism of MHC-mediated protection
from diabetes in the BDC2.5/C57 model will hopefully
suggest avenues for probing the mechanism in the standard
NOD model—and perhaps in humans (for review see ref-
erence 29).
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